Skip to content
type1.science

Medtronic MiniMed Fit (patch pump)

Medtronic

Medtronic's first tubeless ("patch") insulin pump — a semi-durable design pairing a rechargeable reusable base with a disposable component, holding 300 units and worn for 7 days. Built to run the same phone-controlled, Vivera closed-loop algorithm and Simplera Sync / Instinct sensor ecosystem as the tubed MiniMed Flex. Reported FDA submission target is fall 2026, with U.S. availability not expected before 2027 — timeline is uncertain and most specifications are pre-clearance, manufacturer-stated figures.

On the horizonEarly evidencepumptubelesspatchphone-control

The scorecard

Interoperability55

Planned to work with Medtronic's Simplera Sync and Abbott-built Instinct sensors via the shared Flex/Vivera ecosystem, but it is a closed proprietary system with no DIY/open-protocol support and unproven cross-CGM breadth pre-launch.

Reliability45

No published precision, occlusion-detection or human-factors data yet; the Vivera algorithm has only just cleared FDA to begin its pivotal trial, so the track record is entirely pre-clinical/pre-market.

Form factor85

Genuinely tubeless patch worn on-body for up to 7 days; semi-durable (reusable rechargeable base + disposable part) is slightly less seamless than a fully disposable pod but reduces per-wear waste.

Phone control80

Designed around app-only control consistent with the sibling MiniMed Flex (no screen, fully phone-operated), implying phone bolusing — but the dedicated Fit app is unreleased and unverified.

Capacity85

300-unit reservoir is ~50% larger than typical patch pumps, with 7-day wear and a rechargeable battery rated beyond one wear cycle (two batteries supplied) — strong for a tubeless device.

Access & cost20

Not yet submitted to FDA (target fall 2026) and not expected on the U.S. market before 2027; no pricing, reimbursement or ex-US availability confirmed.

The full picture

The Medtronic MiniMed Fit is Medtronic's first tubeless "patch" insulin pump — its bid to compete in a category long dominated by Insulet's Omnipod.1 It is described as a tubeless, patch-style system worn directly on the body, doing away with the tubing and separate handset of a traditional pump.2

Form factor and wear

Unlike Insulet's fully disposable Omnipod, the Fit uses a semi-durable design: a rechargeable, reusable base plus a disposable component.3 Medtronic supplies two rechargeable batteries, each rated to last longer than a full wear cycle, so one charges while the other is in use.4 The reservoir holds 300 units of insulin — roughly 50% more than many patch pumps today — and the device is rated for 7-day wear.5 The pump was developed internally at Medtronic rather than acquired; an earlier plan to buy patch-pump maker EOFlow for about $738 million was abandoned in December 2023 amid a patent dispute with Insulet, after which Medtronic continued building its own.6

Infusion, occlusion detection and reliability

Detailed specifications for the cannula/infusion set and the occlusion-detection system have not been published, and there is no peer-reviewed precision or reliability data yet.7 The controlling Vivera algorithm has only recently received FDA clearance to begin its pivotal trial, so real-world performance, alarms and occlusion handling remain unproven.8 These figures should be read as manufacturer-stated, pre-clearance claims.

CGM, algorithm and DIY compatibility

The Fit is built to share the same algorithm and sensor ecosystem as the tubed MiniMed Flex.9 That means it is intended to run on Medtronic's Vivera algorithm — described as a third-generation full closed-loop system that can bolus automatically for meals or let the user choose a simple meal announcement or full carb count — alongside Medtronic's Simplera Sync disposable sensor and the Abbott-built Instinct sensor.10 The Simplera Sync, an all-in-one disposable CGM, was FDA-approved for Medtronic's automated insulin delivery system in April 2025.11 As a closed, proprietary system, the Fit is not compatible with DIY/open-source loops.

Phone bolusing

Medtronic's next-generation pumps are moving to app-only control: the sibling MiniMed Flex has no screen and is operated entirely from a phone, and the Fit is expected to follow the same phone-first model — implying phone bolusing.12 The dedicated app, however, is unreleased and its features unverified.

Access and cost

The Fit is not yet on the market. Medtronic has reportedly targeted an FDA submission by fall 2026, with analysts expecting U.S. availability no earlier than 2027 — and some cautioning that little material will arrive for roughly three more years.13 No pricing, insurance coverage or non-US (UK/EU) availability has been confirmed; Medtronic has signalled a dual pharmacy and durable-medical-equipment distribution approach.14

What's coming

The near-term milestones are the Vivera pivotal trial and the planned fall-2026 FDA submission, both of which will determine whether the 2027 availability estimate holds.15 Until clearance, every specification here — reservoir size, wear time, occlusion handling, phone bolusing — is a manufacturer or analyst projection, not validated performance. Treat the timeline as uncertain.

References

  1. MassDevice. Next-gen Medtronic insulin pump reportedly set for FDA submission, patch pump on the way. MassDevice (2025). https://www.massdevice.com/next-gen-medtronic-insulin-pump-fda-submission-2026/ ↩

  2. Drug Delivery Business News. Medtronic Diabetes to submit patch pump to FDA by fall 2026. Drug Delivery Business News (2025). https://www.drugdeliverybusiness.com/medtronics-patch-fda-minimed-on-track/ ↩

  3. MedTech Dive. ADA takeaways: Diabetes tech firms preview new patch pumps, glucose sensors. MedTech Dive (2025). https://www.medtechdive.com/news/ada-conference-diabetes-new-pumps-cgms/751482/ ↩

  4. Drug Delivery Business News. Next-gen Medtronic insulin pump reportedly set for FDA submission. Drug Delivery Business News (2025). https://www.drugdeliverybusiness.com/next-gen-medtronic-insulin-pump-fda-submission-2026/ ↩

  5. MedTech Dive. ADA takeaways: Diabetes tech firms preview new patch pumps, glucose sensors. MedTech Dive (2025). https://www.medtechdive.com/news/ada-conference-diabetes-new-pumps-cgms/751482/ ↩

  6. Drug Delivery Business News. Medtronic nixes $738M deal for insulin patch pump maker EOFlow. Drug Delivery Business News (2023). https://www.drugdeliverybusiness.com/medtronic-nixes-738m-deal-for-insulin-patch-pump-maker-eoflow/ ↩

  7. Drug Delivery Business News. Medtronic Diabetes to submit patch pump to FDA by fall 2026. Drug Delivery Business News (2025). https://www.drugdeliverybusiness.com/medtronics-patch-fda-minimed-on-track/ ↩

  8. Diabetech. Medtronic Says MiniMed Spinoff Will Not Delay Next-Gen Pump Launches. Diabetech (2025). https://www.diabetech.info/p/medtronic-says-next-gen-flex-and-fit-insulin-pumps-remain-on-schedule-with-new-sensors-and-algorithm ↩

  9. Diabetech. Medtronic Says MiniMed Spinoff Will Not Delay Next-Gen Pump Launches. Diabetech (2025). https://www.diabetech.info/p/medtronic-says-next-gen-flex-and-fit-insulin-pumps-remain-on-schedule-with-new-sensors-and-algorithm ↩

  10. MedTech Dive. ADA takeaways: Diabetes tech firms preview new patch pumps, glucose sensors. MedTech Dive (2025). https://www.medtechdive.com/news/ada-conference-diabetes-new-pumps-cgms/751482/ ↩

  11. Medtronic. New Simplera Sync sensor for the MiniMed 780G System now FDA approved. Medtronic News (2025). https://news.medtronic.com/2025-04-18-New-Simplera-Sync-TM-sensor-for-the-MiniMed-TM-780G-System-now-FDA-approved ↩

  12. Diabetech. Medtronic Submits MiniMed Flex Pump to the FDA & Tests New Algorithm. Diabetech (2025). https://www.diabetech.info/p/medtronic-submits-minimed-flex-to-the-fda-begins-tests-on-a-next-gen-algorithm ↩

  13. MedTech Dive. ADA takeaways: Diabetes tech firms preview new patch pumps, glucose sensors. MedTech Dive (2025). https://www.medtechdive.com/news/ada-conference-diabetes-new-pumps-cgms/751482/ ↩

  14. Drug Delivery Business News. Next-gen Medtronic insulin pump reportedly set for FDA submission. Drug Delivery Business News (2025). https://www.drugdeliverybusiness.com/next-gen-medtronic-insulin-pump-fda-submission-2026/ ↩

  15. Drug Delivery Business News. Medtronic Diabetes to submit patch pump to FDA by fall 2026. Drug Delivery Business News (2025). https://www.drugdeliverybusiness.com/medtronics-patch-fda-minimed-on-track/ ↩

Coming soon

ETA · FDA submission targeted fall 2026; US availability not expected before 2027 (timeline uncertain)

  • →Vivera algorithm pivotal trial (recently cleared by FDA to begin)
  • →Planned FDA submission of the patch pump · fall 2026
  • →Expected US availability · no earlier than 2027